CLINICAL TRIALS PROFILE FOR RHINOCORT ALLERGY
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Rhinocort Allergy
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT00641979 ↗ | New Nasal Applicator / New Formulation - User Study | Completed | AstraZeneca | Phase 2 | 2002-04-01 | The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR). |
| OTC | NCT06076304 ↗ | Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis | Active, not recruiting | Medstar Health Research Institute | Phase 4 | 2023-11-21 | Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone. |
| OTC | NCT06076304 ↗ | Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis | Active, not recruiting | Patient-Centered Outcomes Research Institute | Phase 4 | 2023-11-21 | Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone. |
| OTC | NCT06076304 ↗ | Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis | Active, not recruiting | Penn State College of Medicine | Phase 4 | 2023-11-21 | Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone. |
| OTC | NCT06076304 ↗ | Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis | Active, not recruiting | University of California, Los Angeles | Phase 4 | 2023-11-21 | Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone. |
| OTC | NCT06076304 ↗ | Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis | Active, not recruiting | University of Washington | Phase 4 | 2023-11-21 | Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Rhinocort Allergy
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00560586 ↗ | Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome | Completed | University of Louisville | Phase 4 | 2004-04-01 | -Intranasal budesonide therapy may lead to improved symptoms and sleep study findings in children with mild obstructive sleep apnea with and without allergic rhinitis that would not be treated with T&A. The aim of the study is to conduct a randomized double blind cross-over trial comparing the effect of once a day intranasal budesonide therapy vs. placebo in children with mild sleep apnea that would not be candidates for T&A. |
| NCT00641212 ↗ | Children, Perennial Allergic Rhinitis (PAR), l-t Growth | Completed | AstraZeneca | Phase 4 | 2000-01-01 | The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months. |
| NCT00641680 ↗ | Rhinocort Aqua Versus Placebo and Fluticasone Propionate | Completed | AstraZeneca | Phase 3 | 2003-04-01 | The purpose of this study is to compare once daily treatment with Rhinocort against placebo and Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis. |
| NCT00641693 ↗ | Assess the Efficacy and Safety of Rhinocort Aqua | Completed | AstraZeneca | Phase 2 | 2004-04-01 | The purpose of this study is to compare Rhinocort with placebo in pediatric subjects aged 2-5 years with allergic rhinitis to study effects on nasal symptoms such as sneezing, runny and stuffy noses. |
| NCT00641979 ↗ | New Nasal Applicator / New Formulation - User Study | Completed | AstraZeneca | Phase 2 | 2002-04-01 | The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR). |
| NCT00826163 ↗ | Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients | Completed | National Science and Technology Development Agency, Thailand | Phase 3 | 2009-01-01 | We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Rhinocort Allergy
Condition Name
Clinical Trial Locations for Rhinocort Allergy
Trials by Country
Clinical Trial Progress for Rhinocort Allergy
Clinical Trial Phase
Clinical Trial Sponsors for Rhinocort Allergy
Sponsor Name
